| Project/Area Number |
25670054
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
Goto Kyoko 金沢大学, 薬学系, 准教授 (50180245)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAMAI Ikumi 金沢大学, 医薬保健研究域薬学系, 教授 (20155237)
|
|---|
| Research Collaborator |
GOTO Masuo University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Research Professor
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | フラボノイド / TEDB / 多剤耐性がん / Collateral sensitivity / 多剤耐性がん細胞 / フラボノイド誘導体 / 異所性P-糖タンパク / 有糸分裂阻害効果 |
|---|
| Outline of Final Research Achievements |
TEDB, a derivative of natural flavonoid desmosdumotin B, selectively inhibits multidrug resistant (MDR) tumor cell growth without any cytotoxicity against normal cells as well as non-MDR cells. Despite its unique antiproliferative activity, the mechanism of action is totally unclear. Using medicinal chemistry as well as chemical biological approaches of TEDB derivatives, we have discovered that TEDB with an artificial benzothiophene ring-B system induced a unique antimitotic bioactivity. The resulting antimitotic agent showed a wide spectrum against multiple cancer cell lines including MDR cells. Based on this finding, a series of new antimitotic flavonoids was designed and synthesized. We have also identified a cellular protein overexpressed in MDR cells as a novel candidate for overcoming MDR tumor using TEDB derivatives.
|
